Lilly to present retatrutide TRIUMPH-2 and orforglipron data at EASD 2026
Retatrutide cut weight by up to 22.5 kg at 80 weeks in adults with obesity and type 2 diabetes, the company said.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 15 11:02 ETSource: grafa.com
The wire
- 01Eli Lilly said Phase 3 TRIUMPH-2 showed average weight reductions up to 49.6 pounds and A1C reductions up to 1.6% at 80 weeks in obesity plus type 2 diabetes.
- 02Phase 3 ACHIEVE-4 data for oral Foundayo (orforglipron) showed non-inferiority to insulin glargine, with hazard ratios of 0.84 for MACE-4 and 0.77 for MACE-3.
- 03Full presentations run September 28 to October 2 in Milan, including Phase 2 data on the eloraTZP combination; figures so far come from company statements, not peer review.
From the source
Read at grafa.comEli Lilly shares diabetes and obesity trial data
Eli Lilly (NYSE:LLY) will present new clinical trial data on retatrutide, Foundayo (orforglipron), and eloraTZP at the European Association for the Study of Diabetes 2026 meeting in Milan from September 28 to October 2.